Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis

Clinical Therapeutics

Volumn 37, Issue 9, 2015, Pages 2086-2103.e10

  Hou, Jing ^a   Xiong, Weiquan ^a   Cao, Ling ^a   Wen, Xiangqiong ^a   Li, Ailing ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

blood pressure; diabetic nephropathy; hyperkalemia; Key words albuminuria; proteinuria; spironolactone

Indexed keywords

ALBUMIN; CREATININE; POTASSIUM; SPIRONOLACTONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST;

ALBUMIN CREATININE RATIO; ALBUMIN PROTEIN EXCRETION; ARTICLE; BLOOD PRESSURE; CHEMICAL PARAMETERS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; EXCRETION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; MEDLINE; META ANALYSIS; POTASSIUM BLOOD LEVEL; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEB OF SCIENCE; ALBUMINURIA; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; URINE;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; SPIRONOLACTONE;

EID: 84941172298     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.05.508     Document Type: Review

References (61)

1. United States Renal Data System 2000 Annual data report 2000 National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. A.C. Powers Diabetes mellitus D.L. Longo, A. Fauci, D. Kasper, S. Hauser, J.L. Jameson, J. Loscalzo, Harrison Principles of Internal Medicine 18th ed 2012 McGraw Hill New York 2968 2984
3. J.B. McGill Diabetes mellitus and related disorders C. Foster, N.F. Mistry, P.F. Peddi, S. Sharma, The Washington Manual of Medical Therapeutics 33rd ed. 2010 793 818
4. J.B. Buse, K.S. Polonsky, and C.F. Burant Type 2 diabetes mellitus Williams Textbook of Endocrinology 2008 Saunders Philadelphia 1329 1354
5. J.B. Lewis, T. Berl, R.P. Bain, and et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy Am J Kidney Dis 34 1999 809 817
6. P. Rossing, E. Hommel, U.M. Smidt, and H.H. Parving Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients Diabetes 42 1993 715 719
7. C. Burton, and K.P. Harris The role of proteinuria in the progression of chronic renal failure Am J Kidney Dis 27 1996 765 775
8. A.I. Adler, R.J. Stevens, S.E. Manley, and et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 2003 225 232
9. R. Retnakaran, C.A. Cull, K.I. Thorne, and et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 Diabetes 55 2006 1832 1839
10. A.A. Eddy, L. McCulloch, E. Liu, and J. Adams A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome Am J Pathol 138 1991 1111 1123
11. P. Hovind, P. Rossing, L. Tarnow, and et al. Progression of diabetic nephropathy Kidney Int 59 2001 702 709
12. P. Fioretto, M.L. Caramori, and M. Mauer The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007 Diabetologia 51 2008 1347 1355
13. R. Amin, B. Widmer, A.T. Prevost, and et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: Prospective observational study BMJ 336 2008 697 701
14. P. Gaede, P. Vedel, N. Larsen, and et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
15. S. Andersen, L. Tarnow, P. Rossing, and et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy Kidney Int 57 2000 601 606
16. B.M. Brenner, M.E. Cooper, D. de Zeeuw, and et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetesand nephropathy N Engl J Med 345 2001 861 869
17. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
18. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, and et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
19. P. Rossing, E. Hommel, U.M. Smidt, and H.H. Parving Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment Diabetologia 37 1994 511 516
20. H.H. Parving, and E. Hommel Prognosis in diabetic nephropathy BMJ 299 1989 230 233
21. T. Berl, L.G. Hunsicker, J.B. Lewis, and et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial J Am Soc Nephrol 16 2005 2170 2179
22. W.F. Keane, Z. Zhang, P.A. Lyle, and et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study Clin J Am Soc Nephrol 1 2006 761 767
23. M. Hase, T. Babazono, N. Ujihara, and Y. Uchigata Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients J Diabetes Invest 4 2013 316 319
24. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
25. D. de Zeeuw, G. Remuzzi, H.H. Parving, and et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL Kidney Int 65 2004 2309 2320
26. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 2009 542 551
27. R.W. Schrier, A. Masoumi, and E. Elhassan Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome Clin J Am Soc Nephrol 5 2010 1132 1140
28. K.J. Schjoedt, K. Rossing, T.R. Juhl, and et al. Beneficial impact of spironolactone in diabetic nephropathy Kidney Int 68 2005 2829 2836
29. J.P. Bertocchio, D.G. Warnock, and F. Jaisser Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease Kidney Int 79 2011 1051 1060
30. A. Chrysostomou, and G. Becker Spironolactone in addition to ACE Inhibition to reduce proteinuria in patients with chronic renal disease N Engl J Med 345 2001 925 926
31. A. Sato, K. Hayashi, M. Naruse, and et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 2003 64 68
32. M. Epstein, G.H. Williams, M. Weinberger, and et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 2006 940 951
33. L. Tylicki, P. Rutkowski, M. Renke, and et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial Am J Kidney Dis 52 2008 486 493
34. S.E. Nielsen, F. Persson, E. Frandsen, and et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo controlled crossover study Diabet Med 59 2012 e184 e190
35. A. Esteghamati, S. Noshad, S. Jarrah, and et al. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial Nephrol Dial Transplant 28 2013 2823 2833
36. T.A. Mavrakanas, K. Gariani, and P.Y. Martin Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review Eur J Intern Med 25 2014 173 176
37. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 7.7.3.5 Medians and Interquartile ranges The Cochrane Collaboration 2011 http://handbook.cochrane.org/
38. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means The Cochrane Collaboration 2011 http://handbook.cochrane.org/
39. G.A. Wells, B. Shea, D. O'Connell, and et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analysis 2004 Ottawa Health Research Institute Ottawa, Ontario
40. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
41. J. Higgins, S. Thompson, J. Deeks, and D. Altman Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice J Health Serv Res Policy 7 2002 51 61
42. R. Rachmani, I. Slavachevsky, M. Amit, and et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study Diabet Med 21 2004 471 475
43. K. Rossing, K.J. Schjoedt, U.M. Smidt, and et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study Diabetes Care 28 2005 2106 2112
44. S. Ogawa, K. Takeuchi, T. Mori, and et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor Clin Exp Pharmacol Physiol 33 2006 477 479
45. K.J. Schjoedt, K. Rossing, T.R. Juhl, and et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy Kidney Int 70 2006 536 542
46. A.H. van den Meiracker, R.G. Baggen, S. Pauli, and et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function J Hypertens 24 2006 2285 2292
47. M.G. Saklayen, L.K. Gyebi, J. Tasosa, and J. Yap Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial J Investig Med 56 2008 714 719
48. U.F. Mehdi, B. Adams-Huet, P. Raskin, and et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 2009 2641 2650
49. S.K. Kota, S. Jammula, S.K. Kota, and et al. Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension Int J Diabetes Dev Ctries 32 2012 33 36
50. A. Momeni, M.S. Behradmanesh, S. Kheiri, and M.K. Horestani Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy J Renin Angiotensin Aldosterone Syst 2013 [Epub ahead of print]
51. S.E. Nielsen, K.J. Schjoedt, K. Rossing, and et al. Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease J Renin Angiotensin Aldosterone Syst 14 2013 161 166
52. A. Ziaee, A. Abbas Vaezi, S. Oveisi, and et al. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial Caspian J Intern Med 4 2013 648 653
53. P.N. Van Buren, B. Adams-Huet, M. Nguyen, and et al. Potassium handling with dual Renin-Angiotensin system inhibition in diabetic nephropathy Clin J Am Soc Nephrol 9 2014 295 301
54. R.E. Schmieder, J.F. Mann, H. Schumacher, and et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease J Am Soc Nephrol 22 2011 1353 1364
55. E.R. Mathiesen, E. Hommel, H.P. Hansen, and et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria Br Med J 319 1999 24 25
56. A.J. Apperloo, D. de Zeeuw, G. van Essen, and P.E. de Jong The initial GFR decline on antihypertensive treatment in long-term intervention studies is reversible after withdrawal of treatment J Am Soc Nephrol 5 1994 324
57. A.V. Chobanian, G.L. Bakris, H.R. Black, and et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure Hypertension 42 2003 1206 1252
58. C.O. Phillips, A. Kashani, D.K. Ko, and et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials Arch Intern Med 167 2007 1930 1936
59. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408 412
60. D. Moher, B. Pham, A. Jones, and et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 1998 609 613
61. J.P. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 16.4.5-4.6 Methods for incorporating cross-over trials into a meta-analysis; Approximate analyses of cross-over trials for a meta-analysis The Cochrane Collaboration 2011 http://handbook.cochrane.org/